New drug cocktail aims to boost transplant success in tough leukemias

This phase 2 trial tests whether adding two drugs (SHR2554 and azacitidine) to standard chemotherapy before a stem cell transplant can help people with high-risk or relapsed/refractory acute leukemia or myelodysplastic syndromes. About 180 participants aged 15-60 will be randomly assigned to receive either the new drug combo plus standard chemo or standard chemo alone, followed by a transplant. The main goal is to see if the combo improves the chance of staying free of cancer relapse or death one year later.